{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T17:15:09Z","timestamp":1794071709154,"version":"4.8.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T00:00:00Z","timestamp":1776211200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100000892","name":"Prostate Cancer Foundation","doi-asserted-by":"publisher","award":["Challenge Award 2023"],"award-info":[{"award-number":["Challenge Award 2023"]}],"id":[{"id":"10.13039\/100000892","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008719","name":"Movember Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008719","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100012187","name":"St. Vincent's Clinic Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100012187","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Prostate Cancer Research Alliance Roy Morgan Pty Ltd Advanced Accelerator Applications"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-026-01140-3","type":"journal-article","created":{"date-parts":[[2026,4,15]],"date-time":"2026-04-15T09:03:33Z","timestamp":1776243813000},"page":"622-630","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Predictive value of early PSMA upregulation for the response to enzalutamide\u2009\u00b1\u2009177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer: substudy of the randomized, phase 2 ENZA-p trial"],"prefix":"10.1038","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4895-7384","authenticated-orcid":false,"given":"Louise","family":"Emmett","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3405-7497","authenticated-orcid":false,"given":"Mina","family":"Swiha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Papa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2138-8633","authenticated-orcid":false,"given":"Shalini","family":"Subramaniam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Crumbaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5159-4580","authenticated-orcid":false,"given":"Anthony M.","family":"Joshua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Weickhardt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sze-Ting","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siobhan","family":"Ng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roslyn J.","family":"Francis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey C.","family":"Goh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A.","family":"Pattison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarennya","family":"Pathmanandavel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8482-4119","authenticated-orcid":false,"given":"Narjess","family":"Ayati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Hofman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8660-4475","authenticated-orcid":false,"given":"Shahneen","family":"Sandhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire","family":"Niu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew J.","family":"Martin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayley","family":"Thomas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3793-8724","authenticated-orcid":false,"given":"Martin R.","family":"Stockler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9066-8244","authenticated-orcid":false,"given":"Ian D.","family":"Davis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"on behalf of the Australian and New Zealand Urogenital and Prostate (ANZUP) Cancer Trials Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,15]]},"reference":[{"key":"1140_CR1","doi-asserted-by":"publisher","first-page":"950","DOI":"10.2967\/jnumed.118.223099","volume":"60","author":"L Emmett","year":"2019","unstructured":"Emmett, L. et al. Rapid modulation of PSMA expression by androgen deprivation: serial (68)Ga-PSMA-11 PET in men with hormone-sensitive and castrate-resistant prostate cancer commencing androgen blockade. J. Nucl. Med. 60, 950\u2013954 (2019).","journal-title":"J. Nucl. Med."},{"key":"1140_CR2","doi-asserted-by":"publisher","first-page":"9578","DOI":"10.1073\/pnas.1106383108","volume":"108","author":"MJ Evans","year":"2011","unstructured":"Evans, M. J. et al. Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc. Natl Acad. Sci. USA 108, 9578\u20139582 (2011).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1140_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s13550-015-0145-8","volume":"5","author":"B Meller","year":"2015","unstructured":"Meller, B. et al. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res. 5, 66 (2015).","journal-title":"EJNMMI Res."},{"key":"1140_CR4","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1002\/pros.22910","volume":"75","author":"JD Murga","year":"2015","unstructured":"Murga, J. D. et al. Synergistic co-targeting of prostate-specific membrane antigen and androgen receptor in prostate cancer. Prostate 75, 242\u2013254 (2015).","journal-title":"Prostate"},{"key":"1140_CR5","doi-asserted-by":"publisher","first-page":"642","DOI":"10.1111\/bju.15491","volume":"128","author":"L Emmett","year":"2021","unstructured":"Emmett, L. et al. ENZA-p trial protocol: a randomized phase II trial using prostate-specific membrane antigen as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901). BJU Int. 128, 642\u2013651 (2021).","journal-title":"BJU Int."},{"key":"1140_CR6","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","volume":"25","author":"L Emmett","year":"2024","unstructured":"Emmett, L. et al. [177Lu]Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial. Lancet Oncol. 25, 563\u2013571 (2024).","journal-title":"Lancet Oncol."},{"key":"1140_CR7","doi-asserted-by":"publisher","first-page":"e1321168","DOI":"10.1080\/23723556.2017.1321168","volume":"4","author":"LA Caromile","year":"2017","unstructured":"Caromile, L. A. & Shapiro, L. H. PSMA redirects MAPK to PI3K-AKT signaling to promote prostate cancer progression. Mol. Cell Oncol. 4, e1321168 (2017).","journal-title":"Mol. Cell Oncol."},{"key":"1140_CR8","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1084\/jem.20171052","volume":"215","author":"C Kaittanis","year":"2018","unstructured":"Kaittanis, C. et al. Prostate-specific membrane antigen cleavage of vitamin B9 stimulates oncogenic signaling through metabotropic glutamate receptors. J. Exp. Med. 215, 159\u2013175 (2018).","journal-title":"J. Exp. Med."},{"key":"1140_CR9","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1007\/s13139-016-0439-4","volume":"51","author":"MK Bakht","year":"2017","unstructured":"Bakht, M. K. et al. Influence of androgen deprivation therapy on the uptake of PSMA-targeted agents: emerging opportunities and challenges. Nucl. Med. Mol. Imaging 51, 202\u2013211 (2017).","journal-title":"Nucl. Med. Mol. Imaging"},{"key":"1140_CR10","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1007\/s00259-020-04944-2","volume":"48","author":"MJ Roberts","year":"2021","unstructured":"Roberts, M. J. et al. 68Ga-PSMA PET\/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. Eur. J. Nucl. Med. Mol. Imaging 48, 477\u2013482 (2021).","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"1140_CR11","doi-asserted-by":"publisher","first-page":"5010","DOI":"10.1200\/JCO.2023.41.16_suppl.5010","volume":"41","author":"BA Hadaschik","year":"2023","unstructured":"Hadaschik, B. A. et al. Prostate-specific membrane antigen ligand positron emission tomography (PSMA-PET) disease extent and overall survival (OS) in patients (pts) with high-risk nonmetastatic castration-resistant prostate cancer (nmCRPC): an international multicenter retrospective study. J. Clin. Oncol. 41, 5010 (2023).","journal-title":"J. Clin. Oncol."},{"key":"1140_CR12","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1200\/JCO.2025.43.5_suppl.46","volume":"43","author":"I de Kouchkovsky","year":"2025","unstructured":"de Kouchkovsky, I. et al. Impact of baseline PSMA PET in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) starting first-line (1L) androgen receptor signaling inhibitor (ARSI) therapy. J. Clin. Oncol. 43, 46 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1140_CR13","doi-asserted-by":"publisher","first-page":"1168","DOI":"10.1016\/S1470-2045(25)00339-0","volume":"26","author":"L Emmett","year":"2025","unstructured":"Emmett, L. et al. Prognostic and predictive value of baseline PSMA-PET total tumour volume and SUVmean in metastatic castration-resistant prostate cancer in ENZA-p (ANZUP1901): a substudy from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 26, 1168\u20131177 (2025).","journal-title":"Lancet Oncol."},{"key":"1140_CR14","first-page":"92","volume":"59","author":"L Emmett","year":"2018","unstructured":"Emmett, L. et al. Modulation of PSMA expression by Androgen deprivation therapy (ADT): serial PSMA PET in men with hormone sensitive, and castrate resistant prostate cancer commencing androgen blockade. J. Nucl. Med. 59, 92 (2018).","journal-title":"J. Nucl. Med."},{"key":"1140_CR15","doi-asserted-by":"crossref","unstructured":"Unterrainer, L. M. et al. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. Eur. J. Nucl. Med. Mol. Imaging pp 3700-3708 (2025).","DOI":"10.1007\/s00259-025-07178-2"},{"key":"1140_CR16","doi-asserted-by":"publisher","first-page":"7431","DOI":"10.3390\/ijms22147431","volume":"22","author":"M Staniszewska","year":"2021","unstructured":"Staniszewska, M. et al. Enzalutamide enhances PSMA expression of PSMA-low prostate cancer. Int. J. Mol. Sci. 22, 7431 (2021).","journal-title":"Int. J. Mol. Sci."},{"key":"1140_CR17","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.2967\/jnumed.120.259069","volume":"62","author":"KA Zukotynski","year":"2021","unstructured":"Zukotynski, K. A. et al. Prospective, single-arm trial evaluating changes in uptake patterns on prostate-specific membrane antigen-targeted (18)F-DCFPyL PET\/CT in patients with castration-resistant prostate cancer starting abiraterone or enzalutamide. J. Nucl. Med. 62, 1430\u20131437 (2021).","journal-title":"J. Nucl. Med."},{"key":"1140_CR18","unstructured":"Emmett, L. et al. Overall survival and quality of life with [177Lu]Lu-PSMA-617 plus enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer (ENZA-p): secondary outcomes from a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. pp291-299 (2025)."},{"key":"1140_CR19","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/S1470-2045(22)00605-2","volume":"23","author":"JP Buteau","year":"2022","unstructured":"Buteau, J. P. et al. PSMA and FDG-PET as predictive and prognostic biomarkers in patients given [177Lu]Lu-PSMA-617 versus cabazitaxel for metastatic castration-resistant prostate cancer (TheraP): a biomarker analysis from a randomised, open-label, phase 2 trial. Lancet Oncol. 23, 1389\u20131397 (2022).","journal-title":"Lancet Oncol."},{"key":"1140_CR20","doi-asserted-by":"publisher","first-page":"5002","DOI":"10.1200\/JCO.2022.40.16_suppl.5002","volume":"40","author":"P Kuo","year":"2022","unstructured":"Kuo, P. et al. [68Ga]Ga-PSMA-11 PET baseline imaging as a prognostic tool for clinical outcomes to [177Lu]Lu-PSMA-617 in patients with mCRPC: A VISION substudy. J. Clin. Oncol. 40, 5002 (2022).","journal-title":"J. Clin. Oncol."},{"key":"1140_CR21","doi-asserted-by":"publisher","first-page":"5011","DOI":"10.1200\/JCO.2025.43.16_suppl.5011","volume":"43","author":"L Emmett","year":"2025","unstructured":"Emmett, L. et al. Predictive and prognostic value of baseline PSMA-PET total tumor volume and SUV mean within ENZA-p, a randomized phase II trial of enzalutamide versus enzalutamide plus [177Lu] Lu-PSMA-617 (ANZUP1901). J. Clin. Oncol. 43, 5011 (2025).","journal-title":"J. Clin. Oncol."},{"key":"1140_CR22","first-page":"330","volume":"16","author":"L Stone","year":"2019","unstructured":"Stone, L. DDR pathway mediates radiosensitization in prostate cancer. Nat. Rev. Urol. 16, 330 (2019).","journal-title":"Nat. Rev. Urol."},{"key":"1140_CR23","doi-asserted-by":"publisher","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"S Gillessen","year":"2024","unstructured":"Gillessen, S. et al. LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): first results of EORTC-GUCG 1333\/PEACE-3. Ann. Oncol. 35, S1254 (2024).","journal-title":"Ann. Oncol."},{"key":"1140_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","volume":"25","author":"MS Hofman","year":"2024","unstructured":"Hofman, M. S. et al. Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial. Lancet Oncol. 25, 99\u2013107 (2024).","journal-title":"Lancet Oncol."},{"key":"1140_CR25","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","volume":"404","author":"MJ Morris","year":"2024","unstructured":"Morris, M. J. et al. 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial. Lancet 404, 1227\u20131239 (2024).","journal-title":"Lancet"},{"key":"1140_CR26","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","volume":"385","author":"O Sartor","year":"2021","unstructured":"Sartor, O. et al. Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer. N. Engl. J. Med. 385, 1091\u20131103 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1140_CR27","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.2967\/jnumed.118.224055","volume":"60","author":"A Gafita","year":"2019","unstructured":"Gafita, A. et al. qPSMA: semiautomatic software for whole-body tumor burden assessment in prostate cancer using 68Ga-PSMA11 PET\/CT. J. Nucl. Med. 60, 1277\u20131283 (2019).","journal-title":"J. Nucl. Med."},{"key":"1140_CR28","doi-asserted-by":"publisher","first-page":"3001","DOI":"10.1038\/s41598-024-53683-z","volume":"14","author":"AM Garcia Vicente","year":"2024","unstructured":"Garcia Vicente, A. M. et al. Analytical performance validation of aPROMISE platform for prostate tumor burden, index and dominant tumor assessment with 18F-DCFPyL PET\/CT. A pilot study. Sci. Rep. 14, 3001 (2024).","journal-title":"Sci. Rep."},{"key":"1140_CR29","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.eururo.2020.04.061","volume":"78","author":"AJ Armstrong","year":"2020","unstructured":"Armstrong, A. J. et al. Five-year survival prediction and safety outcomes with enzalutamide in men with chemotherapy-naive metastatic castration-resistant prostate cancer from the PREVAIL trial. Eur Urol. 78, 347\u2013357 (2020).","journal-title":"Eur Urol."},{"key":"1140_CR30","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1200\/JCO.18.01731","volume":"37","author":"AJ Armstrong","year":"2019","unstructured":"Armstrong, A. J. et al. Prospective multicenter validation of androgen receptor splice variant 7 and hormone therapy resistance in high-risk castration-resistant prostate cancer: the PROPHECY study. J. Clin. Oncol. 37, 1120\u20131129 (2019).","journal-title":"J. Clin. Oncol."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01140-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01140-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01140-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T14:02:30Z","timestamp":1777471350000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-026-01140-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,15]]},"references-count":30,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2026,4]]}},"alternative-id":["1140"],"URL":"https:\/\/doi.org\/10.1038\/s43018-026-01140-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6307229\/v1","asserted-by":"object"}]},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,15]]},"assertion":[{"value":"25 March 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"L.E. reports research grant support (to their institution) from Novartis and Clarity Pharma; consulting fees for lectures or advisory boards from Astellas, Advancell, Janssen, AstraZeneca, Clarity, Novartis, Advancell and Telix in the past 5 years; and philanthropic grant support from the Prostate Cancer Foundation, St Vincent\u2019s Clinic Research Foundation and Curran Foundation. S. Sandhu, reports grants from Novartis\/AAA, AstraZeneca, Merck Sharp & Dohme, Genentech, Pfizer, Amgen and Senhwa to their institution; and personal fees from AstraZeneca, Merck Sharp & Dohme, Bristol Myers Squibb and AstraZeneca to their institution, outside the submitted work. M.S.H. reports grants and receipt of equipment, materials, drugs, medical writing, gifts or other services from the Prostate Cancer Foundation, National Health and Medical Research Council (NHRMC), Movember, US Department of Defense, Medical Research Future Fund, Bayer, Peter MacCallum Foundation, Isotopia and the Australian Nuclear Science and Technology Organisation; consulting fees from Merck Sharp & Dohme and Novartis; honoraria from Janssen, Novartis, AstraZeneca and Astellas; support for meetings from Merck Sharp & Dohme, Novartis, Janssen, AstraZeneca and Astellas; leadership or fiduciary role in other board from Australian Friends of Sheba; and other financial or non-financial interests from Peter MacCallum Cancer Centre and the University of Melbourne. D.P. reports personal fees from Ipsen and Eisai, all outside the submitted work. R.J.F. reports institution funding and consulting fees from AIQ Solutions, outside the submitted work; and committee involvement in the Australasian Radiopharmaceutical Trials Network (unpaid). M.R.S. reports grants to his institution from the Australian NHMRC, Cancer Australia, Astellas, Amgen, AstraZeneca, Bayer, Bionomics, Bristol Myers Squibb, Celgene, Medivation, Merck Sharp & Dohme, Pfizer, Roche, Sanofi and Tilray, all outside the submitted work. I.D.D. reports grants from the NHMRC, during the conduct of the study; and institutional payments to support prostate cancer trials from Pfizer, ANZUP Cancer Trials Group, Bayer, Astellas, Janssen, Movember Foundation and Merck Sharp & Dohme, outside the submitted work. I.D.D. is unremunerated Chair of the ANZUP Cancer Trials Group and is supported in part by an Australian NHMRC Investigator Grant (grant number 2016274). A.M.J. reports consulting or advisory roles (to their institution) from Janssen Oncology, Pfizer and Astellas Pharma; and research funding (to their institution) from Bristol Myers Squibb, Janssen Oncology, Merck Sharp & Dohme, Mayne Pharma, Roche\/Genentech, Bayer, Lilly, Pfizer and AstraZeneca. A.W. declares consulting fees from MSD, Eisai, Bristol Myers Squibb and Astellas; honoraria from Eisai and MSD; and participation on an advisory board from Loxo-Lilly, MSD and Astellas. D.P. declares support for travel from Astellas and participation on an advisory board from Astellas. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}